title: Cognitive-behavioral group therapy versus phenelzine in social phobia: long-term outcome.
abstract: To evaluate the effects of maintenance treatment and durability of gains after treatment discontinuation, responders to either phenelzine (PZ) or cognitive-behavioral group therapy (CBGT) from an acute trial comparing these two treatments as well as pill placebo and a psychotherapy control (educational supportive group therapy) were enrolled into maintenance and treatment-free follow-up phases.
  
  
  METHODS
  Responders to an acute trial contrasting PZ and CBGT entered a six-month maintenance phase. Patients who continued to respond through the maintenance phase entered a six-month treatment free phase. Patients receiving pill placebo or educational supportive group therapy in the acute trial did not enter the long term study.
  
  
  RESULTS
  PZ patients entered maintenance more improved than CBGT patients, and nonrelapsing PZ patients maintained their superior gains throughout the study. Relapse during maintenance did not differ between treatments. However, PZ patients showed a trend toward greater relapse during treatment-free follow-up. There was a greater relapse among patients with generalized social phobia with phenelzine.
  
  
  CONCLUSIONS
  PZ and cognitive-behavioral group therapy may differ in their long term effects. The superiority seen with PZ on some measures in the acute study persisted in patients who maintained their gains over the course of maintenance and treatment-free follow-up. However, CBGT may lead to a greater likelihood of maintaining response after treatment has terminated. Replication with larger samples is needed, as is a study of the acute and long-term efficacy of combined PZ and CBGT.
authors.affiliation: New York State Psychiatric Institute, NY 10032, USA.
authors.forename: M R
authors.initials: MR
authors.lastname: Liebowitz
authors.forename: R G
authors.initials: RG
authors.lastname: Heimberg
authors.forename: F R
authors.initials: FR
authors.lastname: Schneier
authors.forename: D A
authors.initials: DA
authors.lastname: Hope
authors.forename: S
authors.initials: S
authors.lastname: Davies
authors.forename: C S
authors.initials: CS
authors.lastname: Holt
authors.forename: D
authors.initials: D
authors.lastname: Goetz
authors.forename: H R
authors.initials: HR
authors.lastname: Juster
authors.forename: S H
authors.initials: SH
authors.lastname: Lin
authors.forename: M A
authors.initials: MA
authors.lastname: Bruch
authors.forename: R D
authors.initials: RD
authors.lastname: Marshall
authors.forename: D F
authors.initials: DF
authors.lastname: Klein
mesh_terms: D000328:Adult; D000704:Analysis of Variance; D016009:Chi-Square Distribution; D015928:Cognitive Behavioral Therapy; D015986:Confounding Factors, Epidemiologic; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use*; D010352:Patient Dropouts; D010624:Phenelzine / Q000627:therapeutic use*; D010698:Phobic Disorders / Q000188:drug therapy / Q000628:therapy*; D011379:Prognosis; D011615:Psychotherapy, Group; D012008:Recurrence
chemical_list: D008996:Monoamine Oxidase Inhibitors; D010624:Phenelzine